Revvity Cash Flow from Investing Activities 2010-2024 | RVTY
Revvity annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Revvity cash flow from investing activities for the quarter ending March 31, 2024 was $-0.018B, a 100.98% decline year-over-year.
- Revvity cash flow from investing activities for the twelve months ending March 31, 2024 was $4.317B, a 180.37% increase year-over-year.
- Revvity annual cash flow from investing activities for 2023 was $1.314B, a 1088.72% decline from 2022.
- Revvity annual cash flow from investing activities for 2022 was $-0.133B, a 96.77% decline from 2021.
- Revvity annual cash flow from investing activities for 2021 was $-4.113B, a 715.22% increase from 2020.
| Revvity Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2023 | $1,314 |
| 2022 | $-133 |
| 2021 | $-4,113 |
| 2020 | $-504 |
| 2019 | $-488 |
| 2018 | $-160 |
| 2017 | $-1,267 |
| 2016 | $-84 |
| 2015 | $-101 |
| 2014 | $-296 |
| 2013 | $-1 |
| 2012 | $-80 |
| 2011 | $-910 |
| 2010 | $295 |
| 2009 | $-154 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.191B | $2.751B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $125.903B | 15.80 |
| Cencora (COR) | United States | $47.741B | 18.61 |
| ICON (ICLR) | Ireland | $26.139B | 24.68 |
| DiDi Global (DIDIY) | China | $21.386B | 0.00 |
| Avantor (AVTR) | United States | $15.283B | 22.50 |
| CochLear (CHEOY) | Australia | $14.173B | 0.00 |
| Natera (NTRA) | United States | $13.190B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.644B | 41.60 |
| Viatris (VTRS) | United States | $12.466B | 3.73 |
| Charles River Laboratories (CRL) | United States | $10.809B | 20.69 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.137B | 0.00 |
| Solventum (SOLV) | United States | $8.860B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.681B | 0.00 |
| HealthEquity (HQY) | United States | $7.198B | 46.21 |
| Organon (OGN) | United States | $5.431B | 5.15 |
| Bausch + Lomb (BLCO) | Canada | $5.256B | 21.04 |
| Doximity (DOCS) | United States | $5.107B | 35.77 |
| PACS (PACS) | United States | $4.437B | 0.00 |
| Life Times (LTH) | United States | $3.623B | 37.96 |
| Sotera Health (SHC) | United States | $3.369B | 16.53 |
| Surgery Partners (SGRY) | United States | $3.017B | 27.60 |
| GoodRx Holdings (GDRX) | United States | $2.859B | 108.86 |
| Agilon Health (AGL) | United States | $2.677B | 0.00 |
| Progyny (PGNY) | United States | $2.487B | 42.82 |
| AMN Healthcare Services Inc (AMN) | United States | $2.029B | 8.04 |
| NovoCure (NVCR) | Jersey | $2.014B | 0.00 |
| Premier (PINC) | United States | $1.949B | 8.34 |
| BrightSpring Health Services (BTSG) | United States | $1.852B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.757B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.566B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.449B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.226B | 0.00 | |
| CareDx (CDNA) | United States | $0.749B | 0.00 |
| Embecta (EMBC) | United States | $0.722B | 4.91 |
| GeneDx Holdings (WGS) | United States | $0.717B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.695B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.680B | 7.21 |
| Auna S.A (AUNA) | Luxembourg | $0.568B | 0.00 |
| Sharecare (SHCR) | United States | $0.497B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.437B | 11.45 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.430B | 0.00 |
| Enhabit (EHAB) | United States | $0.426B | 42.50 |
| ModivCare (MODV) | United States | $0.367B | 6.87 |
| Sonida Senior Living (SNDA) | United States | $0.345B | 0.00 |
| DocGo (DCGO) | United States | $0.310B | 16.94 |
| LifeMD (LFMD) | United States | $0.288B | 0.00 |
| MultiPlan (MPLN) | United States | $0.238B | 0.00 |
| Beauty Health (SKIN) | United States | $0.223B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.212B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.204B | 0.00 |
| Biodesix (BDSX) | United States | $0.189B | 0.00 |
| So-Young (SY) | China | $0.111B | 53.49 |
| Pono Capital Two (PTWO) | United States | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.044B | 5.88 |
| Co-Diagnostics (CODX) | United States | $0.043B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.035B | 0.00 |
| Oncology Institute (TOI) | United States | $0.031B | 0.00 |
| Nutex Health (NUTX) | United States | $0.029B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.025B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.024B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.023B | 0.00 |
| OncoCyte (OCX) | United States | $0.022B | 0.00 |
| KindlyMD (KDLY) | $0.018B | 0.00 | |
| BIMI Holdings (BIMI) | United States | $0.015B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.005B | 0.00 |
| DermTech (DMTK) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.004B | 0.00 |
| OpGen (OPGN) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Assure Holdings (IONM) | United States | $0.002B | 0.00 |